Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101

•Haploidentical bone marrow transplantation (haplo-BMT) is moderately cost-effective compared with umbilical cord blood transplantation for persons age <65 years and cost-saving for those age >65 years.•Haplo-BMT is a fair value choice for commercially insured patients with high-risk leukemia and lymphoma who need hematopoietic stem cell transplantation.•For Medicare enrollees, haplo-BMT is a preferred choice when considering cost and outcomes.